Follow The Filings

ELVN Enliven Therapeutics

Enliven Therapeutics earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ELVN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ELVN insider trades
  • None no insider bought on the open market
  • $52.6M sold by 3 insiders outside a trading plan
  • $24.3M sold by 8 insiders under 10b5-1 plans
  1. Benjamin Hohl CFO
    Planned sale
    $232K 6,018 shares at $38.48 14% of stake
    Traded Oct 19 Filed Oct 21
    ↗
  2. Helen Louise Collins Chief Medical Officer
    Planned sale
    $192K 5,000 shares at $38.47 17% of stake
    Traded Oct 19 Filed Oct 21
    ↗
  3. J. Scott Garland Director
    Sale
    $607K 13,000 shares at $46.67 100% of stake
    Traded Oct 1 Filed Oct 5
    ↗
  4. Benjamin Hohl CFO
    Planned sale
    $303K 6,018 shares at $50.35 14% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  5. Helen Louise Collins Chief Medical Officer
    Planned sale
    $252K 5,000 shares at $50.35 17% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  6. Benjamin Hohl CFO
    Planned sale
    $353K 6,018 shares at $58.58 13% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  7. Helen Louise Collins Chief Medical Officer
    Planned sale
    $293K 5,000 shares at $58.59 17% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  8. Mika K Derynck Director
    Planned sale
    $9.6M 158,795 shares at $60.21 100% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  9. Benjamin Hohl CFO
    Planned sale
    $317K 6,018 shares at $52.64 12% of stake
    Traded Jul 17 Filed Jul 21
    ↗
  10. Helen Louise Collins Chief Medical Officer
    Planned sale
    $263K 5,000 shares at $52.67 17% of stake
    Traded Jul 17 Filed Jul 21
    ↗
  11. Lori Anne Kunkel Director
    Planned sale
    $505K 10,000 shares at $50.49 19% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  12. Orbimed Advisors LLC 10% owner, +2 joint filers
    Sale
    $39M 860,123 shares at $45.36 12% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  13. Benjamin Hohl CFO
    Planned sale
    $264K 6,018 shares at $43.80 11% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  14. Helen Louise Collins Chief Medical Officer
    Planned sale
    $219K 5,000 shares at $43.80 17% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  15. Orbimed Advisors LLC 10% owner, +2 joint filers
    Sale
    $12.7M 281,408 shares at $45.02 3.7% of stake
    Traded Jun 15 Filed Jun 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 option exercises and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.